Social media

In just a few days, ICON will be at #DPHARM2025, 16–17 September at the Loews Philadelphia Hotel. Stop by booth #305 to learn how ICON’s comprehensive expertise in clinical development, consulting, and commercialization ...

Biomarkers aren’t just supporting drug development, they’re driving it. This expert-led report produced in conjunction with Drug Target Review explores how biomarker science is advancing trial design, accelerating clinic...

Latest issue out now. If you, like our thousands of subscribers, would like a convenient way to keep on top of the latest regulatory authority updates, sign up to our free newsletter today. Compiled and collated by ICON...

ICON invites you to connect with our biomarker experts Sean Downing and Jin Li at WorldCDx. We work across all major platforms including next generation sequencing, ddPCR, flow cytometry, histopathology and immunohistoch...

For over 20 years, ICON has supported the development of biosimilars, complex molecules that are highly comparable to their reference biologic drugs. With the large number of biologics losing patent exclusivity over th...

With just two weeks to go, ICON will be at OCT Southern California, booth #26, where our team of experts will introduce you to ICON’s capabilities and explore how biotech and pharma sponsors can accelerate study start-up...

Patient voices matter more than ever in obesity research. Join our upcoming webinar to learn how to combine COAs and digital health technologies to capture the full patient experience. https://ow.ly/mWIK50WLeLf #Clinic...

Early-stage biotech companies face unique #challenges in clinical development. That’s why having partners capable of delivering integrated support - from early development through to trial execution, is crucial. Read th...

Symphony Health, an ICON plc company, are looking forward to Fierce Pharma Week (Sept 8–11) in Philadelphia. Visit us at booth #1320 to explore how our medical affairs, commercial, and promotional solutions help connect...

The next in our UK regulatory environment blog series is out now. In this instalment we discuss the opportunity for interactions with both the MHRA and the National Institute for Health and Care Excellence (NICE). These ...

There are many considerations that set oncology biosimilar development apart from that of novel biologics. Read ICON’s article in Drug Discovery & Development magazine to better prepare for challenges such as developing ...

Clinical data submissions require careful planning, consistency and a strong understanding of agency expectations. This whitepaper explores how regulatory teams can prepare unified materials that meet the requirements of...